View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
May 6, 2021

Coronavirus company news summary – Alberta reports first blood clot death linked to AZ vaccine – Health Canada approves Pfizer/BioNTech jab for adolescents aged 12-15

By Chris Lo

The Canadian province of Alberta has recorded its first death following a rare blood clot in a patient after receiving the AstraZeneca vaccine against Covid-19. The incident marks the second blood clot case and the first death after more than 253,000 doses of the vaccine were given in the province.

Pfizer and BioNTech’s Covid-19 vaccine has received expanded authorisation from Canadian health regulator Health Canada  for use among teenagers aged between 12 and 15 years. Health Canada approved the use of vaccine following study of data from a Phase III clinical trial in participants aged 12 to 15 years. The participants will be monitored for long-term protection and safety for another two years, following their second dose. Another paediatric study testing the vaccine’s efficacy in children aged six months to 11 years is currently underway.

Moderna has reported initial data from a Phase II study demonstrating that a 50µg dose of mRNA-1273 or mRNA-1273.351 administered as a booster to previously inoculated individuals achieved higher antibody titer responses against the Brazil (P.1) and South African (B.1.351) Covid-19 variants. The booster dose of mRNA-1273.351 achieved greater neutralising antibody titers against the B.1.351 variant than the mRNA-1273 booster dose. The company is currently evaluating multivalent vaccine booster candidate mRNA-1273.211.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU